AGA Family of Websites:

AGA invests in EvoEndo, opportunity fund closes to investors April 30

Our latest investment supports a novel new medical device for unsedated transnasal endoscopy.
EvoEndo products image
EvoEndo products image

AGA’s invested in EvoEndo, a medical device company developing platforms for unsedated transnasal endoscopy (TNE). This marks the fund’s fourth investment. Read about our first three investments: Virgo, EndoSound and NeXtGen Biologics. If you’re interested in becoming an investor, hurry. The fund closes April 30.

The EvoEndo® Single-Use Endoscopy System received FDA 510(k) clearance in February 2022. The EvoEndo System includes a sterile, single-use, flexible gastroscope designed for unsedated transnasal upper endoscopy and a small portable video controller. Unsedated TNE can be used to evaluate and diagnose a wide range of upper GI conditions that may require frequent monitoring, including eosinophilic esophagitis (EoE), dysphagia, celiac disease, gastroesophageal reflux disease, Barrett’s esophagus, malabsorption and abdominal pain. 

EvoEndo’s technology allows pediatric patients and adults alike to consider an unsedated option for routine endoscopies without the use of general anesthesia or sedation, which also allows hospitals to move endoscopy procedures from an ambulatory procedural suite to an office-based environment and allows the “traditional” sedation procedure rooms to be used for more complex, therapeutic cases. 

Brought to you by the
AGA Center for GI Innovation and Technology

AGA clinical guidance

Find the latest evidence-based recommendations for treating your patients.